Subject(s)
Abdominal Neoplasms/etiology , Agenesis of Corpus Callosum , Ganglioneuroma/etiology , Mediastinal Neoplasms/etiology , Neural Crest/pathology , Neuroblastoma/etiology , Abdominal Neoplasms/embryology , Abdominal Neoplasms/therapy , Abnormalities, Drug-Induced , Child , Child, Preschool , Combined Modality Therapy , Dicyclomine , Doxylamine/adverse effects , Drug Combinations , Female , Fetal Alcohol Spectrum Disorders/complications , Ganglioneuroma/embryology , Ganglioneuroma/therapy , Growth Disorders/complications , Humans , Male , Mediastinal Neoplasms/embryology , Mediastinal Neoplasms/therapy , Neuroblastoma/embryology , Neuroblastoma/therapy , Pregnancy , Prenatal Exposure Delayed Effects , Pyridoxine/adverse effects , Remission InductionABSTRACT
In this study of 467 healthy term infants seen for routine 1-year health maintenance examination, we determined the influence of mild prior infection on the concentration of hemoglobin and other laboratory evidence of iron deficiency. In addition we studied the Hgb response in 261 infants randomized to receive a 3-month course of treatment with either iron or placebo. Infants who had had one or more clinic visits because of infection during the previous 3 months or who were reported as not being entirely well during the past month or who had an elevated sedimentation rate were more likely to have anemia or "low normal" Hgb, higher erythrocyte protoporphyrin and serum ferritin values, and lower serum iron concentration than infants who had been well. Hgb response greater than or equal to 1 gm/dl after iron treatment occurred more commonly in infants who had had prior visits because of infection. The results indicate that upper respiratory and other mild antecedent infections commonly predispose to iron deficiency (probably because of a decrease in iron absorption).
Subject(s)
Anemia, Hypochromic/blood , Infections/blood , Anemia, Hypochromic/drug therapy , Blood Sedimentation , Erythrocyte Indices , Ferritins/analysis , Hemoglobins/analysis , Humans , Infant , Iron/therapeutic use , Time Factors , Transferrin/analysisABSTRACT
The neurotoxicity of vincristine sulfate, a commonly used antineoplastic agent, has been well described. A literature review failed to reveal any absolute contraindications to the initial use of vincristine. We describe two patients with nodular sclerosing Hodgkin's disease in whom a rapidly progressive, but reversible, severe polyneuropathy developed when they were given a total of 4 mg of vincristine sulfate. Each was later shown to have the demyelinating form of Charcot-Marie-Tooth syndrome. This association suggests that the use of vincristine is contraindicated in patients with the demyelinating form of Charcot-Marie-Tooth syndrome.
